Relaxation effect of phosphodiesterase-5 inhibitor on the animal bladder and prostatic urethra

In vitro and in vivo study

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Aim: To assess the relaxation effect of the phosphodiesterase-5 inhibitor udenafil on the bladder and prostatic urethra and its therapeutic potentials for benign prostatic hyperplasia (BPH)/lower urinary tract symptoms (LUTS). Methods: For the in vitro study, muscle strips from urinary bladder and urethra were prepared from male New Zealand rabbits. The strips were mounted in organ baths and connected to force transducers. After stabilization, maximal tissue contractions were obtained by the addition of phenylepinephrine for urethra strips and carbachol for bladder strips. When the contraction was stabilized, a dose-response curve of udenafil was constructed. For the in vivo study using adult male Sprague-Dawley rats, changes of intravesical pressure and urethral perfusion pressure after intraarterial administration of udenafil were monitored. Results: Udenafil significantly relaxed the bladder and urethra strips in a dose-dependent manner. At 10-3 M, udenafil induced a significant relaxation of the bladder strips by 37.3% and of the urethra strips by 44.0%. In the in vivo study, the intercontraction interval was significantly prolonged (p < 0.01) and the duration of urethral relaxation with high-frequency oscillations was significantly prolonged (p < 0.01) after udenafil. Conclusions: Udenafil had relaxant effects on the bladder and prostatic urethral smooth muscle. Clinically, udenafil could be applied as an effective treatment for BPH/LUTS.

Original languageEnglish
Pages (from-to)231-235
Number of pages5
JournalUrologia Internationalis
Volume84
Issue number2
DOIs
Publication statusPublished - 2010 Mar 1

Fingerprint

udenafil
Phosphodiesterase 5 Inhibitors
Urethra
Urinary Bladder
Lower Urinary Tract Symptoms
Prostatic Hyperplasia
Pressure
In Vitro Techniques
Carbachol
Transducers
Baths

Keywords

  • Benign prostatic hyperplasia
  • Lower urinary tract symptoms
  • Phosphodiesterase-5 inhibitor
  • Udenafil

ASJC Scopus subject areas

  • Urology

Cite this

@article{e15ec41316a0461d9ec821629f4f6669,
title = "Relaxation effect of phosphodiesterase-5 inhibitor on the animal bladder and prostatic urethra: In vitro and in vivo study",
abstract = "Aim: To assess the relaxation effect of the phosphodiesterase-5 inhibitor udenafil on the bladder and prostatic urethra and its therapeutic potentials for benign prostatic hyperplasia (BPH)/lower urinary tract symptoms (LUTS). Methods: For the in vitro study, muscle strips from urinary bladder and urethra were prepared from male New Zealand rabbits. The strips were mounted in organ baths and connected to force transducers. After stabilization, maximal tissue contractions were obtained by the addition of phenylepinephrine for urethra strips and carbachol for bladder strips. When the contraction was stabilized, a dose-response curve of udenafil was constructed. For the in vivo study using adult male Sprague-Dawley rats, changes of intravesical pressure and urethral perfusion pressure after intraarterial administration of udenafil were monitored. Results: Udenafil significantly relaxed the bladder and urethra strips in a dose-dependent manner. At 10-3 M, udenafil induced a significant relaxation of the bladder strips by 37.3{\%} and of the urethra strips by 44.0{\%}. In the in vivo study, the intercontraction interval was significantly prolonged (p < 0.01) and the duration of urethral relaxation with high-frequency oscillations was significantly prolonged (p < 0.01) after udenafil. Conclusions: Udenafil had relaxant effects on the bladder and prostatic urethral smooth muscle. Clinically, udenafil could be applied as an effective treatment for BPH/LUTS.",
keywords = "Benign prostatic hyperplasia, Lower urinary tract symptoms, Phosphodiesterase-5 inhibitor, Udenafil",
author = "Lee, {Jeong Gu} and Moon, {Du Geon} and Kang, {Seok Ho} and Cho, {Dae Yeon} and Park, {Hong Seok} and Bae, {Jae Hyun}",
year = "2010",
month = "3",
day = "1",
doi = "10.1159/000277604",
language = "English",
volume = "84",
pages = "231--235",
journal = "Urologia Internationalis",
issn = "0042-1138",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Relaxation effect of phosphodiesterase-5 inhibitor on the animal bladder and prostatic urethra

T2 - In vitro and in vivo study

AU - Lee, Jeong Gu

AU - Moon, Du Geon

AU - Kang, Seok Ho

AU - Cho, Dae Yeon

AU - Park, Hong Seok

AU - Bae, Jae Hyun

PY - 2010/3/1

Y1 - 2010/3/1

N2 - Aim: To assess the relaxation effect of the phosphodiesterase-5 inhibitor udenafil on the bladder and prostatic urethra and its therapeutic potentials for benign prostatic hyperplasia (BPH)/lower urinary tract symptoms (LUTS). Methods: For the in vitro study, muscle strips from urinary bladder and urethra were prepared from male New Zealand rabbits. The strips were mounted in organ baths and connected to force transducers. After stabilization, maximal tissue contractions were obtained by the addition of phenylepinephrine for urethra strips and carbachol for bladder strips. When the contraction was stabilized, a dose-response curve of udenafil was constructed. For the in vivo study using adult male Sprague-Dawley rats, changes of intravesical pressure and urethral perfusion pressure after intraarterial administration of udenafil were monitored. Results: Udenafil significantly relaxed the bladder and urethra strips in a dose-dependent manner. At 10-3 M, udenafil induced a significant relaxation of the bladder strips by 37.3% and of the urethra strips by 44.0%. In the in vivo study, the intercontraction interval was significantly prolonged (p < 0.01) and the duration of urethral relaxation with high-frequency oscillations was significantly prolonged (p < 0.01) after udenafil. Conclusions: Udenafil had relaxant effects on the bladder and prostatic urethral smooth muscle. Clinically, udenafil could be applied as an effective treatment for BPH/LUTS.

AB - Aim: To assess the relaxation effect of the phosphodiesterase-5 inhibitor udenafil on the bladder and prostatic urethra and its therapeutic potentials for benign prostatic hyperplasia (BPH)/lower urinary tract symptoms (LUTS). Methods: For the in vitro study, muscle strips from urinary bladder and urethra were prepared from male New Zealand rabbits. The strips were mounted in organ baths and connected to force transducers. After stabilization, maximal tissue contractions were obtained by the addition of phenylepinephrine for urethra strips and carbachol for bladder strips. When the contraction was stabilized, a dose-response curve of udenafil was constructed. For the in vivo study using adult male Sprague-Dawley rats, changes of intravesical pressure and urethral perfusion pressure after intraarterial administration of udenafil were monitored. Results: Udenafil significantly relaxed the bladder and urethra strips in a dose-dependent manner. At 10-3 M, udenafil induced a significant relaxation of the bladder strips by 37.3% and of the urethra strips by 44.0%. In the in vivo study, the intercontraction interval was significantly prolonged (p < 0.01) and the duration of urethral relaxation with high-frequency oscillations was significantly prolonged (p < 0.01) after udenafil. Conclusions: Udenafil had relaxant effects on the bladder and prostatic urethral smooth muscle. Clinically, udenafil could be applied as an effective treatment for BPH/LUTS.

KW - Benign prostatic hyperplasia

KW - Lower urinary tract symptoms

KW - Phosphodiesterase-5 inhibitor

KW - Udenafil

UR - http://www.scopus.com/inward/record.url?scp=77949420591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949420591&partnerID=8YFLogxK

U2 - 10.1159/000277604

DO - 10.1159/000277604

M3 - Article

VL - 84

SP - 231

EP - 235

JO - Urologia Internationalis

JF - Urologia Internationalis

SN - 0042-1138

IS - 2

ER -